UBS Group
NRIX icon

UBS Group’s Nurix Therapeutics NRIX Stock Holding History

UBS Group’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$22.2M Sell
917,117
-59,245
-6% -$1.01M ﹤0.01% 2574
2026
Q1 		$15.1M Buy
976,362
+552,937
+131% +$9.17M ﹤0.01% 2890
2025
Q4 		$8.03M Buy
423,425
+60,879
+17% +$875K ﹤0.01% 3533
2025
Q3 		$3.35M Sell
362,546
-1,226,494
-77% -$12.7M ﹤0.01% 4453
2025
Q2 		$18.1M Buy
1,589,040
+915,893
+136% +$9.9M ﹤0.01% 2469
2025
Q1 		$8M Buy
673,147
+598,034
+796% +$10M ﹤0.01% 3291
2024
Q4 		$1.42M Sell
75,113
-27,753
-27% -$636K ﹤0.01% 5033
2024
Q3 		$2.31M Sell
102,866
-15,697
-13% -$356K ﹤0.01% 3855
2024
Q2 		$2.47M Sell
118,563
-50,379
-30% -$785K ﹤0.01% 3545
2024
Q1 		$2.48M Buy
168,942
+92,540
+121% +$995K ﹤0.01% 3724
2023
Q4 		$788K Sell
76,402
-95,600
-56% -$655K ﹤0.01% 4695
2023
Q3 		$1.35M Buy
172,002
+91,355
+113% +$834K ﹤0.01% 3826
2023
Q2 		$806K Sell
80,647
-4,461
-5% -$45.5K ﹤0.01% 4429
2023
Q1 		$756K Sell
85,108
-59,194
-41% -$617K ﹤0.01% 4351
2022
Q4 		$1.58M Buy
144,302
+102,511
+245% +$1.24M ﹤0.01% 3616
2022
Q3 		$545K Sell
41,791
-17,550
-30% -$278K ﹤0.01% 4260
2022
Q2 		$752K Sell
59,341
-89,363
-60% -$1.01M ﹤0.01% 3960
2022
Q1 		$2.08M Buy
148,704
+49,367
+50% +$876K ﹤0.01% 3387
2021
Q4 		$2.88M Buy
99,337
+98,762
+17,176% +$2.99M ﹤0.01% 3404
2021
Q3 		$17K Sell
575
-18,958
-97% -$585K ﹤0.01% 7342
2021
Q2 		$518K Sell
19,533
-12,909
-40% -$379K ﹤0.01% 4709
2021
Q1 		$1.01M Buy
+32,442
New +$1.23M ﹤0.01% 4232

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS Group's NRIX Position: Q2 2026 in Review

UBS Group reduced its Nurix Therapeutics (NRIX) stake by 6.1% in Q2 2026, selling an estimated $1.01M and leaving 917,117 shares worth $22.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2574.

UBS Group first reported a position in NRIX in Q1 2021 and has held it in 22 quarters since. 212 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • UBS Group held 917,117 shares of Nurix Therapeutics worth $22.2M as of Q2 2026.
  • UBS Group sold 59,245 Nurix Therapeutics shares in Q2 2026, an estimated $1.01M.
  • Nurix Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #2574 holding.
  • UBS Group first reported a position in Nurix Therapeutics in Q1 2021 and has held it in 22 quarters since.
  • 212 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.